[go: up one dir, main page]

WO2008001182A8 - Tricyclic heteroaryl compounds as pde10 inhibitors - Google Patents

Tricyclic heteroaryl compounds as pde10 inhibitors

Info

Publication number
WO2008001182A8
WO2008001182A8 PCT/IB2007/001696 IB2007001696W WO2008001182A8 WO 2008001182 A8 WO2008001182 A8 WO 2008001182A8 IB 2007001696 W IB2007001696 W IB 2007001696W WO 2008001182 A8 WO2008001182 A8 WO 2008001182A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
tricyclic heteroaryl
disorders
heteroaryl compounds
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/001696
Other languages
French (fr)
Other versions
WO2008001182A1 (en
Inventor
Patrick Robert Verhoest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to CA002654394A priority Critical patent/CA2654394A1/en
Priority to JP2009517466A priority patent/JP2009541481A/en
Publication of WO2008001182A1 publication Critical patent/WO2008001182A1/en
Publication of WO2008001182A8 publication Critical patent/WO2008001182A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention pertains to tricyclic heteroaryl compounds of formula (I) that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds which are selective inhibitors of PDElO. The invention further relates to pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom.
PCT/IB2007/001696 2006-06-26 2007-06-15 Tricyclic heteroaryl compounds as pde10 inhibitors Ceased WO2008001182A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002654394A CA2654394A1 (en) 2006-06-26 2007-06-15 Tricyclic heteroaryl compounds as pde10 inhibitors
JP2009517466A JP2009541481A (en) 2006-06-26 2007-06-15 Tricyclic heteroaryl compounds as PDE10 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80576106P 2006-06-26 2006-06-26
US60/805,761 2006-06-26

Publications (2)

Publication Number Publication Date
WO2008001182A1 WO2008001182A1 (en) 2008-01-03
WO2008001182A8 true WO2008001182A8 (en) 2008-12-11

Family

ID=38608399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/001696 Ceased WO2008001182A1 (en) 2006-06-26 2007-06-15 Tricyclic heteroaryl compounds as pde10 inhibitors

Country Status (3)

Country Link
JP (1) JP2009541481A (en)
CA (1) CA2654394A1 (en)
WO (1) WO2008001182A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI501965B (en) 2008-06-20 2015-10-01 Lundbeck & Co As H Novel phenylimidazole derivatives as pde10a enzyme inhibitors
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
PL2393360T3 (en) 2009-02-05 2016-04-29 Takeda Pharmaceuticals Co Pyridazinone compounds
BRPI1009637A2 (en) 2009-06-05 2019-04-30 Cephalon, Inc compound, composition and use of a compound
EA022705B1 (en) 2010-06-24 2016-02-29 Такеда Фармасьютикал Компани Лимитед CONDENSED HETEROCYCLIC COMPOUNDS AS PHOSPHODYSTERASE INHIBITORS (PDE) Inhibitors
WO2012018058A1 (en) 2010-08-04 2012-02-09 武田薬品工業株式会社 Fused heterocyclic ring compound
EP2601192B1 (en) 2010-08-04 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP2604597B1 (en) 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a
EP2687529B1 (en) 2011-03-16 2016-07-13 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2013045607A1 (en) * 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
RU2014123352A (en) 2011-11-09 2015-12-20 Эббви Дойчланд Гмбх Унд Ко. Кг HETEROCYCLIC CARBOXAMIDES USEFUL AS PHOSPHODESTERASE TYPE 10A INHIBITORS
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
US9464085B2 (en) 2012-08-17 2016-10-11 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
EP2895489B1 (en) 2012-09-17 2017-10-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
CA2902655A1 (en) 2013-03-14 2014-09-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
EP2975037A4 (en) 2013-03-15 2016-08-10 Daiichi Sankyo Co Ltd BENZOTHIOPHENE DERIVATIVE
EP3856185A1 (en) 2018-09-28 2021-08-04 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110452A (en) * 1977-10-17 1978-08-29 E. R. Squibb & Sons, Inc. Pyrazolo (1,5-c) quinazoline derivatives and related compounds
AU2002227985A1 (en) * 2000-12-13 2002-06-24 Bayer Aktiengesellschaft Pyrrolo (2.1-a) dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
WO2003014115A1 (en) * 2001-08-06 2003-02-20 Bayer Aktiengesellschaft 3-substituted pyrrolo (2.1-a) isoquinoline derivatives
BRPI0511854A (en) * 2004-06-07 2008-01-15 Pfizer Prod Inc phosphodiestearase 10 inhibition as a treatment for obesity-related and metabolic syndrome-related conditions

Also Published As

Publication number Publication date
WO2008001182A1 (en) 2008-01-03
CA2654394A1 (en) 2008-01-03
JP2009541481A (en) 2009-11-26

Similar Documents

Publication Publication Date Title
WO2008001182A8 (en) Tricyclic heteroaryl compounds as pde10 inhibitors
WO2007129183A3 (en) Bicyclic heteroaryl compounds as pde10 inhibitors
WO2008020302A3 (en) Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2007077490A3 (en) Bicyclic heteroaryl compounds as pde10 inhibitors
MX2007006301A (en) Pyrrolidyl derivatives of heteroaromatic compounds as phosphodiesterase inhibitors.
MY142052A (en) Heteroaromatic quinoline compounds
WO2007085954A3 (en) Aminophthalazine derivative compounds
WO2005082883A3 (en) Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
TW200616641A (en) Novel piperidyl derivatives of quinazoline and isoquinoline
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
WO2011051342A8 (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
MX2012013197A (en) Indazole inhibitors of kinase.
WO2008006051A3 (en) Bicyclic heteroaryl inhibitors of pde4
WO2010006130A3 (en) Pde-10 inhibitors
MX2011005093A (en) Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors.
WO2007103370A3 (en) Quinazoline derivatives as phosphodiesterase 10 inhibitors
WO2007100610A3 (en) Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators
WO2008011006A3 (en) Methods for treating pain and screening analgesic compounds
WO2007070433A3 (en) 2-arylthiazole derivatives as cxcr3 receptor modulators
HK1202861A1 (en) Quinoline derivatives as pde10a enzyme inhibitors
DOP2007000001A (en) BICYCLE HETEROARILO COMPOUNDS AS PDE10 INHIBITORS
DOP2005000273A (en) NOVEDOUS PIRROLIDILE DERIVATIVES OF HETEROAROMATIC COMPOUNDS
UA98112C2 (en) Bicyclic heteroaryl inhibitors of phosphodiesterase pde4

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07734881

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2654394

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009517466

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07734881

Country of ref document: EP

Kind code of ref document: A1